Paysign Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Paysign de 35.2% y 17.5% respectivamente, mientras que el BPA crecerá en un 28.5% al año.
Información clave
35.2%
Tasa de crecimiento de los beneficios
28.51%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Diversified Financial | 8.0% |
| Tasa de crecimiento de los ingresos | 17.5% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 20
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.Actualización de narrativa • Apr 30
PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.Actualización de narrativa • Apr 12
PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.Actualización de narrativa • Mar 28
PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.Artículo de análisis • Feb 05
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Artículo de análisis • Nov 16
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Seeking Alpha • Oct 01
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking AlphaArtículo de análisis • Aug 09
Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
Actualización de narrativa • Aug 07
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.Artículo de análisis • May 06
Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...Artículo de análisis • Mar 04
Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...Artículo de análisis • Dec 27
Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 20
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
Nueva narrativa • Sep 26
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.Artículo de análisis • Sep 07
Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Aug 02
Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Seeking Alpha • Jun 30
Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking AlphaArtículo de análisis • Apr 26
Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...Artículo de análisis • Mar 29
Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Jan 25
Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)
PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2027 | 125 | 20 | N/A | N/A | 5 |
| 12/31/2026 | 109 | 15 | N/A | N/A | 5 |
| 3/31/2026 | 91 | 10 | 70 | 77 | N/A |
| 12/31/2025 | 82 | 8 | 44 | 52 | N/A |
| 9/30/2025 | 75 | 8 | 10 | 19 | N/A |
| 6/30/2025 | 69 | 7 | -17 | -8 | N/A |
| 3/31/2025 | 64 | 6 | -1 | 9 | N/A |
| 12/31/2024 | 58 | 4 | 13 | 23 | N/A |
| 9/30/2024 | 56 | 8 | 23 | 32 | N/A |
| 6/30/2024 | 54 | 8 | 48 | 56 | N/A |
| 3/31/2024 | 50 | 7 | 25 | 33 | N/A |
| 12/31/2023 | 47 | 6 | 21 | 28 | N/A |
| 9/30/2023 | 44 | 2 | -8 | -1 | N/A |
| 6/30/2023 | 42 | 1 | 4 | 9 | N/A |
| 3/31/2023 | 40 | 1 | 18 | 23 | N/A |
| 12/31/2022 | 38 | 1 | 21 | 25 | N/A |
| 9/30/2022 | 36 | 0 | 27 | 30 | N/A |
| 6/30/2022 | 33 | -1 | 11 | 14 | N/A |
| 3/31/2022 | 31 | -1 | 8 | 10 | N/A |
| 12/31/2021 | 29 | -3 | 13 | 15 | N/A |
| 9/30/2021 | 28 | -7 | 14 | 17 | N/A |
| 6/30/2021 | 20 | -13 | 25 | 27 | N/A |
| 3/31/2021 | 20 | -12 | 10 | 13 | N/A |
| 12/31/2020 | 24 | -9 | 10 | 14 | N/A |
| 9/30/2020 | 27 | -3 | 14 | 18 | N/A |
| 6/30/2020 | 36 | 6 | -2 | 3 | N/A |
| 3/31/2020 | 38 | 8 | 3 | 7 | N/A |
| 12/31/2019 | 35 | 7 | N/A | 17 | N/A |
| 9/30/2019 | 32 | 6 | N/A | 18 | N/A |
| 6/30/2019 | 29 | 4 | N/A | 29 | N/A |
| 3/31/2019 | 26 | 3 | N/A | 34 | N/A |
| 12/31/2018 | 23 | 3 | N/A | 16 | N/A |
| 9/30/2018 | 21 | 2 | N/A | 12 | N/A |
| 6/30/2018 | 19 | 2 | N/A | 10 | N/A |
| 3/31/2018 | 17 | 2 | N/A | 7 | N/A |
| 12/31/2017 | 15 | 2 | N/A | 7 | N/A |
| 9/30/2017 | 14 | 2 | N/A | 6 | N/A |
| 6/30/2017 | 12 | 2 | N/A | 3 | N/A |
| 3/31/2017 | 11 | 2 | N/A | 5 | N/A |
| 12/31/2016 | 10 | 1 | N/A | 4 | N/A |
| 9/30/2016 | 10 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 9 | -2 | N/A | 3 | N/A |
| 3/31/2016 | 9 | -2 | N/A | 0 | N/A |
| 12/31/2015 | 8 | -2 | N/A | -1 | N/A |
| 9/30/2015 | 11 | 0 | N/A | 3 | N/A |
| 6/30/2015 | 11 | 3 | N/A | 3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (35.2% al año) de PAYS es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (35.2% al año) de PAYS crezcan más rápidamente que el mercado US (16.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de PAYS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (17.5% al año) de PAYS crezcan más rápidamente que los del mercado US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 17.5% al año) de PAYS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PAYS se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 06:25 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Paysign, Inc. está cubierta por 6 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |